ARS Pharmaceuticals

Yahoo Finance • last month

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * 3D Systems Corporation (DDD [https://seekingalpha.com/symbol/DDD]) * FuelCell Energy (FCEL [https://seekingalpha.com/symbol/FCEL]) * Zim Integrated Shipping Services Ltd.... Full story

Yahoo Finance • 2 months ago

Dan Loeb's Third Point takes new stake in Chipotle Mexican Grill, Alibaba in Q4 moves

Dan Loeb's Third Point took new stakes in Chipotle Mexican Grill (CMG [https://seekingalpha.com/symbol/CMG]), Alibaba (BABA [https://seekingalpha.com/symbol/BABA]), and Spotify (SPOT [https://seekingalpha.com/symbol/SPOT]), while increasin... Full story

Yahoo Finance • 2 months ago

Got $300? 2 Biotech Stocks to Buy and Hold Forever

Krystal Biotech(NASDAQ: KRYS) and ARS Pharmaceuticals(NASDAQ: SPRY) have been gaining a lot of attention over the past year, thanks to the potential in their groundbreaking -- and for now, only -- commercial therapies. In 2023, Krystal pi... Full story

Yahoo Finance • 3 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from... Full story

Yahoo Finance • 5 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that co... Full story

Yahoo Finance • 5 months ago

ARS Pharmaceuticals targets renewed growth in 2026 as neffy adoption accelerates and new global launches begin

Earnings Call Insights: ARS Pharmaceuticals (SPRY) Q3 2025 MANAGEMENT VIEW * Richard Lowenthal, Co-Founder, President, CEO & Director, highlighted a pivotal quarter for ARS Pharma, stating "U.S. net product revenue for neffy grew again... Full story

Yahoo Finance • 5 months ago

ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M

* ARS Pharmaceuticals press release [https://seekingalpha.com/pr/20299947-ars-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights-for-neffy] (SPRY [https://seekingalpha.com/symbol/SPRY]): Q3 GAAP EPS of -$0.52 mis... Full story

Yahoo Finance • 5 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with... Full story

Yahoo Finance • 5 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation reports about 9 out of every 10 patients experiencing anaphylaxis w... Full story

Yahoo Finance • 6 months ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-ris... Full story

Yahoo Finance • 7 months ago

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 months ago

neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to marke... Full story

Yahoo Finance • 7 months ago

ARS Pharma drops 9% as Lupin files application for generic neffy

[Move down arrow on blackboard background] * ARS Pharmaceuticals (NASDAQ:SPRY [https://seekingalpha.com/symbol/SPRY]) is down ~9% in Friday trading after disclosing that Indian drugmaker Lupin has filed an ANDA with the U.S. FDA for a g... Full story

Yahoo Finance • 8 months ago

ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists

ARS Pharmaceuticals Inc (NASDAQ:SPRY [https://www.chartmill.com/stock/quote/SPRY/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $15... Full story

Yahoo Finance • 8 months ago

ARS Pharmaceuticals GAAP EPS of -$0.46 beats by $0.01, revenue of $15.72M beats by $1.94M

* ARS Pharmaceuticals press release [https://seekingalpha.com/pr/20199129-ars-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-accelerating] (NASDAQ:SPRY [https://seekingalpha.com/symbol/SPRY]): Q2 GAAP EPS of... Full story

Yahoo Finance • 9 months ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to marketEURneffy in the U.K., expects avai... Full story

Yahoo Finance • 10 months ago

Silverback Therapeutics stock hits 52-week high at $18.59

Silverback Therapeutics Inc . (NASDAQ:SPRY) stock reached a significant milestone as it hit a 52-week high of $18.59, with the company now commanding a market capitalization of $1.81 billion. According to InvestingPro data, the stock’s tec... Full story

Yahoo Finance • 10 months ago

Ars pharma CCO Karas sells $240k in SPRY stock

Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a company whose stock has delivered a remarkable 104% return over the past year and currently commands a market capitalization of $1.55 billion, sold 15,000 s... Full story

Yahoo Finance • 11 months ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that cou... Full story

Yahoo Finance • 11 months ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

ARS Pharmaceuticals, Inc. $7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promo... Full story